Q-omics provides the consensus-scored ZNF620 profile across patient tissues and cancer cell-line models. ZNF620 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF620 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF620 RNA expression shows 21,745 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KIRC, and ACC as cancer lineages where ZNF620 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF620 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF620 survival associations across molecular data types. ZNF620 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF620 RNA expression–survival associations across cancer types. High ZNF620 expression shows unfavorable associations in ACC and LIHC, but favorable associations in BRCA, KIRC, READ and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF620 RNA expression.
This table summarizes ZNF620 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF620. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF620 shows lower tumor expression in KIRC, THCA and LUSC and higher tumor expression in LIHC, COAD and UCEC. The KIRC box plot shows higher ZNF620 RNA expression in normal versus tumor tissue (log2 FC = −0.675, t-test p < 0.001).
This table shows molecular features associated with ZNF620 in patient tissues and cancer cell lines. In patient samples, ZNF620 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF620 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
